BCR-ABL1 doubling times according to the clinical context. The doubling times suggest a complete lack of kinase inhibition for patients with BC and those who discontinued imatinib or had a complete interruption, compared with partial kinase inhibition for patients with mutations who maintained CP. *Significant differences between the doubling times (P < .0001), compared with the BC, discontinued in CMR and complete interruption groups.